Eli Lilly (LLY) announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.In the study, muvalaplin led to a significant reduction in elevated Lp(a) levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp(a) from baseline to week 12.  Using an intact Lp(a) assay, the reductions in Lp(a) levels were 47.6% for the 10 mg dose, 81.7% ...